BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/16/2024 6:17:54 AM | Browse: 181 | Download: 758
 |
Received |
|
2024-03-11 08:43 |
|
Peer-Review Started |
|
2024-03-11 08:43 |
|
First Decision by Editorial Office Director |
|
2024-05-11 08:33 |
|
Return for Revision |
|
2024-05-11 08:33 |
|
Revised |
|
2024-05-21 09:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-06-05 02:46 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-05 07:52 |
|
Articles in Press |
|
2024-06-05 07:52 |
|
Edit the Manuscript by Language Editor |
|
2024-06-12 13:40 |
|
Typeset the Manuscript |
|
2024-06-21 01:21 |
|
Publish the Manuscript Online |
|
2024-07-16 06:17 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Gui-Qin Peng, Hai-Chi Song and Wan-Yi Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Wu Jieping Medical Foundation |
320.6750.2022.20.25 |
| Chongqing Health Commission |
﹝2020﹞68 |
|
| Corresponding Author |
Wan-Yi Chen, MSc, Associate Chief Pharmacist, Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Shapingba District, Chongqing 400030, China. wanyichen_cquch@163.com |
| Key Words |
Non-small cell lung cancer; Epidermal growth factor receptor; C-ros oncogene 1; Co-mutation; Treatment strategies; Case report |
| Core Tip |
Over the past two decades, molecular targeted therapies have improved clinical outcomes significantly for non-small cell lung cancer (NSCLC) patients with both epidermal growth factor receptor (EGFR) mutation and c-ros oncogene 1 (ROS1) fusion. Nevertheless, EGFR/ROS1 co-mutation is a rare event in NSCLC, and the standard treatment for such cases is still equivocal. We reported an EGFR/ROS1 co-mutation in an NSCLC patient who remained clinically stable after 53 months of treatment with crizotinib. This is the longest progression-free survival reported in the literature. This case suggested that crizotinib may be a potential choice for NSCLC patients with the EGFR/ROS1 co-mutation. |
| Publish Date |
2024-07-16 06:17 |
| Citation |
Peng GQ, Song HC, Chen WY. Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report. World J Clin Oncol 2024; 15(7): 945-952 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i7/945.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i7.945 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
